A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
Research Grant
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
February 1, 2016
End Date
June 29, 2018
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
February 1, 2016
End Date
June 29, 2018